OptimizeRx (OPRX) delivered earnings and revenue surprises of +1,300.00% and +7.59%, respectively, for the quarter ended March 2026. Do the numbers...

OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.

OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.

OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.

OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.

TTD misses earnings estimates despite revenue growth, as slowing momentum, macro pressures and rising competition challenge its near-term outlook.

ZTS misses on Q1 earnings and cuts its 2026 revenue outlook as weaker U.S. companion animal sales pressured results, sending shares down in pre-market...

OPRX launched a programmatic EHR ad connection for DSPs, expanding point-of-care targeting and access to authenticated inventory.

GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.

Globus Medical beats Q1 EPS estimates by 22% as revenues rise 27% to $759.9M; margins widen and 2026 EPS outlook up, lifting shares 5.8%.